Jazz Pharmaceuticals 已获得 FDA 批准，推出 Modeyso（dordaviprone），用于治疗罕见脑癌弥漫性中线胶质瘤（伴有 H3 K27M 突变），这种癌症主要影响年轻人。该药物通过以 9.35 亿美元收购 Chimerix 获得，被批准用于一岁及以上在先前治疗后癌症已进展的患者。由于治疗选择有限且疾病复发不可避免，此次批准标志着一个重要里程碑。Jazz 正在进行一项...
Source LinkJazz Pharmaceuticals 已获得 FDA 批准，推出 Modeyso（dordaviprone），用于治疗罕见脑癌弥漫性中线胶质瘤（伴有 H3 K27M 突变），这种癌症主要影响年轻人。该药物通过以 9.35 亿美元收购 Chimerix 获得，被批准用于一岁及以上在先前治疗后癌症已进展的患者。由于治疗选择有限且疾病复发不可避免，此次批准标志着一个重要里程碑。Jazz 正在进行一项...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.